NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

GILD

Gilead Sciences, Inc

Apr 23 • 04:00PM ET

106.38

Dollar change +0.87
Percentage change 0.82	%

Healthcare • Drug Manufacturers - General • USA • NASD

Peers: ABBV BMY MRK PFE AMGN JNJ LLY VRTX REGN BIIB

| Held by: VTI VOO QQQ SPY IVV VTV XLV VYM IBB VHT

Scroll to Statements

Index	NDX, S&P 500	P/E	289.78	EPS (ttm)	0.37	Insider Own	0.20%	Shs Outstand	1.25B	Perf Week	0.66%
Market Cap	132.62B	Forward P/E	12.48	EPS next Y	8.52	Insider Trans	-23.51%	Shs Float	1.24B	Perf Month	-0.34%
Income	480.00M	PEG	11.36	EPS next Q	1.78	Inst Own	86.47%	Short Float	1.72%	Perf Quarter	14.34%
Sales	28.73B	P/S	4.62	EPS this Y	72.71%	Inst Trans	1.42%	Short Ratio	2.30	Perf Half Y	22.67%
Book/sh	15.51	P/B	6.86	EPS next Y	6.83%	ROA	0.79%	Short Interest	21.39M	Perf Year	59.35%
Cash/sh	9.28	P/C	11.46	EPS next 5Y	25.52%	ROE	2.28%	52W Range	62.07 - 119.96	Perf YTD	15.17%
Dividend Est.	3.10 (2.91%)	P/FCF	12.87	EPS past 5Y	-38.13%	ROI	1.07%	52W High	-11.32%	Beta	0.30
Dividend TTM	3.10 (2.91%)	Quick Ratio	1.45	Sales past 5Y	5.30%	Gross Margin	78.24%	52W Low	71.39%	ATR (14)	3.56
Dividend Ex-Date	Mar 14, 2025	Current Ratio	1.60	EPS Y/Y TTM	-91.54%	Oper. Margin	37.11%	RSI (14)	48.68	Volatility	3.03% 3.47%
Employees	17600	Debt/Eq	1.41	Sales Y/Y TTM	6.16%	Profit Margin	1.67%	Recom	1.83	Target Price	115.90
Option/Short	Yes / Yes	LT Debt/Eq	1.31	EPS Q/Q	24.48%	Payout	805.23%	Rel Volume	0.84	Prev Close	105.51
Sales Surprise	5.82%	EPS Surprise	9.35%	Sales Q/Q	6.39%	Earnings	Apr 24 AMC	Avg Volume	9.29M	Price	106.38
SMA20	-0.76%	SMA50	-2.46%	SMA200	16.48%	Trades		Volume	7,767,733	Change	0.82%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight	$125
Mar-04-25	Reiterated	Oppenheimer	Outperform	$115 → $132
Feb-18-25	Upgrade	Deutsche Bank	Hold → Buy	$120
Feb-13-25	Upgrade	DZ Bank	Hold → Buy	$108
Jan-10-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$87 → $113
Dec-10-24	Resumed	BofA Securities	Buy	$109
Nov-15-24	Initiated	Wolfe Research	Outperform	$110
Nov-14-24	Initiated	Citigroup	Buy	$125
Nov-08-24	Downgrade	Maxim Group	Buy → Hold
Oct-21-24	Upgrade	Leerink Partners	Market Perform → Outperform	$74 → $96
Oct-17-24	Initiated	Bernstein	Outperform	$105
Oct-07-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$78 → $100
Jul-08-24	Upgrade	Raymond James	Mkt Perform → Outperform	$93
May-01-24	Reiterated	Maxim Group	Buy	$90 → $85
Apr-24-24	Upgrade	HSBC Securities	Reduce → Hold	$69
Feb-22-24	Downgrade	Truist	Buy → Hold	$91 → $82
Nov-09-23	Initiated	Deutsche Bank	Hold	$75
Sep-08-23	Upgrade	BofA Securities	Neutral → Buy	$88 → $95
Sep-06-23	Initiated	HSBC Securities	Reduce	$71
Jul-24-23	Reiterated	Barclays	Equal Weight	$81 → $80

Show Previous Ratings

Today 12:37PM	Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More (Zacks)
09:25AM	The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi (Zacks)
08:04AM	Gilead Sciences (GILD) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Apr-22-25 02:29PM	Regeneron to Report Q1 Earnings: What's in Store for the Stock? (Zacks)
10:28AM	Gilead reports topline data from Phase III trial of Trodelvy combo therapy (Clinical Trials Arena)
10:01AM	Loading…
10:01AM	Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for (Zacks)
09:52AM	Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds? (Insider Monkey)
09:48AM	Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy (Investing.com)
09:06AM	Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast? (Zacks)
03:27AM	Polaris Global Equity Composite Q1 2025 Commentary (Seeking Alpha)
Apr-21-25 01:36PM	Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum? (Zacks)
08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
08:30AM	Trodelvy Plus Keytruda Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer (Business Wire)
Apr-18-25 09:40AM	Here's Why Gilead Sciences (GILD) is a Strong Value Stock (Zacks)
09:15AM	What Analyst Projections for Key Metrics Reveal About Gilead (GILD) Q1 Earnings (Zacks)
05:07PM	Loading…
Apr-17-25 05:07PM	Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential (Seeking Alpha)
01:06PM	Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings? (Zacks)
10:01AM	Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
08:10AM	My Dividend Stock Portfolio: New All-Time Dividend Record In March - 100 Holdings With 15 Buys (Seeking Alpha)
06:20AM	Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar? (Zacks)
06:20AM	Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now? (Zacks)
06:20AM	Should You Invest in the Invesco Pharmaceuticals ETF (PJP)? (Zacks)
Apr-16-25 06:00PM	Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know (Zacks)
01:05PM	Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now? (Zacks)
09:54AM	Is Gilead Sciences Inc. (NASDAQ:GILD) the Most Undervalued Quality Stock to Buy Now? (Insider Monkey)
09:00AM	Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know (Zacks)
07:20AM	Dodge & Cox Balanced Fund Q1 2025 Shareholder Letter (Seeking Alpha)
06:20AM	Should First Trust NASDAQ-100 Ex-Technology Sector ETF (QQXT) Be on Your Investing Radar? (Zacks)
06:20AM	Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? (Zacks)
05:55AM	Dodge & Cox Stock Fund Q1 2025 Shareholder Letter (Seeking Alpha)
08:50AM	Loading…
Apr-15-25 08:50AM	Gilead Sciences: Advancing Oncology Care Through Gilead's Research Scholars Program (ACCESSWIRE)
05:05AM	3 Reasons GILD is Risky and 1 Stock to Buy Instead (StockStory)
Apr-14-25 06:20AM	Should First Trust NASDAQ-100 Equal Weighted ETF (QQEW) Be on Your Investing Radar? (Zacks)
Apr-11-25 05:30AM	How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs (The Wall Street Journal)
Apr-10-25 04:05PM	Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025 (Business Wire)
08:50AM	PatientView Ranks Gilead 'Best' at ESG (ACCESSWIRE)
Apr-09-25 05:50PM	Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know (Zacks)
03:59PM	Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out (Seeking Alpha)
12:10PM	Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report? (Zacks)
08:50AM	Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1 (Insider Monkey)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
07:00AM	ClearBridge Value Strategy Q1 2025 Commentary (Seeking Alpha)
07:00AM	2 Top Dividend Stocks That Could Set You Up for Life (Motley Fool)
06:20AM	Should You Invest in the SPDR S&P Biotech ETF (XBI)? (Zacks)
Apr-08-25 09:40AM	Gilead Sciences: The Global Health Challenge of HIV and Hepatitis B Coinfections (ACCESSWIRE)
06:20AM	Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now? (Zacks)
Apr-07-25 01:22PM	5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025 (Zacks)
09:40AM	ClearBridge Dividend Strategy Q1 2025 Commentary (Seeking Alpha)
09:30AM	Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
06:20AM	Should You Invest in the iShares Biotechnology ETF (IBB)? (Zacks)
Apr-04-25 01:45PM	Bayer's Vividion Initiates Dosing in Early-Stage Cancer Study (Zacks)
08:27AM	4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues (Zacks)
Apr-03-25 06:26PM	Stocks are Going on Sale, Time to be Greedy While Others are Fearful? (Zacks)
05:50PM	Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note (Zacks)
10:46AM	Roche's Higher Dose of Ocrevus Fails to Meet Goal in RMS Study (Zacks)
10:46AM	FDA Grants Accelerated Approval to NVS Kidney Disease Drug (Zacks)
09:45AM	The Centrifuge Sessions: Driving Innovation and Investment in Cancer Research (ACCESSWIRE)
08:00AM	Gilead: HIV Franchise Woes Highlight Cancer Follies (Seeking Alpha)
Apr-02-25 06:00PM	Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note (Zacks)
03:48PM	Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts (Seeking Alpha)
02:57PM	Final Trades: Gilead Sciences, Amazon, Alphabet and KLA Corp. (CNBC TV)
09:40AM	Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term (Zacks)
09:00AM	Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
11:40AM	GILD or AMGN: Which Is the Better Value Stock Right Now? (Zacks)
11:32AM	Impax U.S. Sustainable Economy Fund Q4 2024 Commentary (Seeking Alpha)
11:00AM	10 Stocks of the S&P 500 ETF Up More Than 20% in Q1 (Zacks)
09:30AM	J&J's Third Bankruptcy Attempt to End Talc Suits Rejected (Zacks)
08:55AM	Discovering a Breakthrough: Gilead's Long-Standing Commitment to Helping Change the Course of HIV (ACCESSWIRE)
08:15AM	2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating (MarketBeat)
07:30AM	These biotech names aren't facing 'huge concern' from tariffs (Yahoo Finance Video)
07:15AM	Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company (Seeking Alpha)
Mar-31-25 05:50PM	Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
09:57AM	Moderna, biotech stocks slide on resignation of FDA official Peter Marks (Yahoo Finance)
09:57AM	Moderna, biotech stocks slide following resignation of FDA official Peter Marks (Yahoo Finance)
09:17AM	Hartford Quality Value ETF Q4 2024 Commentary (Seeking Alpha)
Mar-30-25 08:00AM	Earn A Potentially 12%-15% Income: Monthly Options Series (April 2025) (Seeking Alpha)
05:00AM	Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors (Seeking Alpha)
03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
02:50AM	abrdn Healthcare Investors Q4 2024 Commentary (Seeking Alpha)
Mar-27-25 06:25PM	Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Franklin Biotechnology Discovery Fund Q4 2024 Commentary (SeekingAlpha)
Mar-26-25 12:45PM	Gileads HIV Treatments Could Face Headwinds. Why the Stock Will Still Rise. (Barrons.com)
11:53AM	Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag (Zacks)
11:51AM	AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint (Zacks)
09:40AM	Are Medical Stocks Lagging Gilead Sciences (GILD) This Year? (Zacks)
07:43AM	SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study (Zacks)
Mar-25-25 03:00PM	Bayer Down on Verdict to Pay $2.1B to Plaintiff in Roundup Litigation (Zacks)
12:44PM	Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition? (Zacks)
12:04PM	Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2% (Zacks)
11:51AM	UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study (Zacks)
09:25AM	Gilead Sciences: Using Lessons From the HIV Epidemic To Help Reduce Stigma Around Lung Cancer (ACCESSWIRE)
08:40AM	CorMedix (CRMD) Q4 Earnings and Revenues Beat Estimates (Zacks)
Mar-24-25 05:50PM	Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
02:36PM	EMA Accepts GSK's Filing for Expanded Use of Nucala in COPD (Zacks)
06:20AM	Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? (Zacks)
Mar-23-25 12:36PM	Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval (SeekingAlpha)
Mar-22-25 12:31AM	Dividend Champion, Contender, And Challenger Highlights: Week Of March 23 (SeekingAlpha)
Mar-21-25 02:10PM	FDA Approves Novartis Drug for Rare Kidney Disease Treatment (Zacks)
12:46PM	Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy (Zacks)

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dickinson Andrew D	Chief Financial Officer	Apr 15 '25	Sale	106.40	2,500	266,000	168,174	Apr 16 03:22 PM
ANDREW DICKINSON	Officer	Apr 15 '25	Proposed Sale	106.40	2,500	266,000		Apr 15 04:04 PM
Dickinson Andrew D	Chief Financial Officer	Mar 17 '25	Sale	110.53	2,500	276,325	170,674	Mar 18 04:37 PM
ANDREW DICKINSON	Officer	Mar 17 '25	Proposed Sale	110.53	2,500	276,325		Mar 17 04:16 PM
Dickinson Andrew D	Chief Financial Officer	Mar 10 '25	Option Exercise	63.91	17,929	1,145,842	186,990	Mar 12 06:41 PM
Dickinson Andrew D	Chief Financial Officer	Mar 10 '25	Sale	118.17	17,929	2,118,696	169,061	Mar 12 06:41 PM
ANDREW DICKINSON	Officer	Mar 10 '25	Proposed Sale	118.17	17,929	2,118,695		Mar 10 04:02 PM
MERDAD V PARSEY	Officer	Mar 03 '25	Proposed Sale	115.70	21,910	2,534,913		Mar 03 04:26 PM
GILEAD SCIENCES, INC.	10% Owner	Feb 18 '25	Buy	11.00	1,363,636	14,999,996	31,424,760	Feb 20 07:42 PM
Dickinson Andrew D	Chief Financial Officer	Feb 18 '25	Sale	104.09	2,500	260,225	169,061	Feb 19 04:43 PM
ANDREW DICKINSON	Officer	Feb 18 '25	Proposed Sale	104.09	2,500	260,225		Feb 18 04:14 PM
Dickinson Andrew D	Chief Financial Officer	Feb 12 '25	Option Exercise	67.27	137,676	9,260,873	308,899	Feb 13 09:13 PM
Dickinson Andrew D	Chief Financial Officer	Feb 12 '25	Sale	102.22	137,676	14,073,241	171,223	Feb 13 09:13 PM
ANDREW DICKINSON	Officer	Feb 12 '25	Proposed Sale	102.22	137,676	14,073,241		Feb 12 04:03 PM
Dickinson Andrew D	Chief Financial Officer	Jan 31 '25	Option Exercise	67.52	142,180	9,600,576	273,053	Feb 03 06:09 PM
Dickinson Andrew D	Chief Financial Officer	Jan 31 '25	Sale	97.22	142,180	13,822,740	129,873	Feb 03 06:09 PM
ANDREW DICKINSON	Officer	Jan 31 '25	Proposed Sale	97.22	142,180	13,822,740		Jan 31 04:15 PM
MERDAD V PARSEY	Officer	Jan 31 '25	Proposed Sale	98.00	184,683	18,098,989		Jan 31 04:01 PM
Dickinson Andrew D	Chief Financial Officer	Jan 15 '25	Sale	91.35	2,500	228,375	129,873	Jan 16 03:31 PM
ANDREW DICKINSON	Officer	Jan 15 '25	Proposed Sale	91.35	2,500	228,375		Jan 15 04:18 PM
GILEAD SCIENCES, INC.	10% Owner	Dec 19 '24	Buy	21.37	940,499	20,098,464	2,209,471	Dec 23 08:26 PM
GILEAD SCIENCES, INC.	10% Owner	Dec 18 '24	Buy	1.04	1,759,978	1,830,377	9,105,451	Dec 19 04:19 PM
Dickinson Andrew D	Chief Financial Officer	Dec 16 '24	Sale	91.96	8,500	781,660	132,373	Dec 17 05:27 PM
ANDREW DICKINSON	Officer	Dec 16 '24	Proposed Sale	91.96	8,500	781,660		Dec 16 04:08 PM
Dickinson Andrew D	Chief Financial Officer	Nov 29 '24	Option Exercise	70.50	248,645	17,528,577	387,564	Dec 03 02:43 PM
Dickinson Andrew D	Chief Financial Officer	Nov 29 '24	Sale	92.76	248,645	23,065,271	138,919	Dec 03 02:43 PM
Parsey Merdad	Chief Medical Officer	Nov 27 '24	Option Exercise	62.44	145,413	9,079,689	245,012	Nov 29 08:10 PM
Parsey Merdad	Chief Medical Officer	Nov 27 '24	Sale	91.92	164,211	15,094,013	80,801	Nov 29 08:10 PM
ANDREW DICKINSON	Officer	Nov 29 '24	Proposed Sale	92.76	248,645	23,065,258		Nov 29 02:35 PM
Bluestone Jeffrey	Director	Nov 26 '24	Option Exercise	61.24	10,000	612,442	15,708	Nov 27 06:14 PM
Bluestone Jeffrey	Director	Nov 26 '24	Sale	91.39	6,788	620,356	8,920	Nov 27 06:14 PM
MERDAD V PARSEY	Officer	Nov 27 '24	Proposed Sale	91.92	164,211	15,094,008		Nov 27 04:15 PM
Bluestone Jeffrey	Director	Nov 26 '24	Proposed Sale	91.39	6,788	620,356		Nov 26 07:31 PM
Mercier Johanna	Chief Commercial Officer	Nov 06 '24	Sale	91.28	5,000	456,400	73,127	Nov 07 04:38 PM
Parsey Merdad	Chief Medical Officer	Nov 06 '24	Option Exercise	57.92	25,000	1,448,000	125,189	Nov 07 04:32 PM
Parsey Merdad	Chief Medical Officer	Nov 06 '24	Sale	91.50	25,590	2,341,485	99,599	Nov 07 04:32 PM
MERDAD V PARSEY	Officer	Nov 06 '24	Proposed Sale	91.50	25,590	2,341,485		Nov 06 04:19 PM
JOHANNA MERCIER	Officer	Nov 06 '24	Proposed Sale	91.28	5,000	456,400		Nov 06 04:07 PM
Parsey Merdad	Chief Medical Officer	Oct 01 '24	Sale	83.83	2,000	167,660	100,189	Oct 02 04:58 PM
MERDAD V PARSEY	Officer	Oct 01 '24	Proposed Sale	83.83	2,000	167,660		Oct 01 04:27 PM
Parsey Merdad	Chief Medical Officer	Sep 12 '24	Option Exercise	57.92	25,000	1,448,000	123,435	Sep 13 07:07 PM
Parsey Merdad	Chief Medical Officer	Sep 12 '24	Sale	84.50	21,246	1,795,287	102,189	Sep 13 07:07 PM
Mercier Johanna	Chief Commercial Officer	Sep 12 '24	Sale	83.78	29,357	2,459,577	78,127	Sep 13 05:08 PM
MERDAD V PARSEY	Officer	Sep 12 '24	Proposed Sale	84.50	21,246	1,795,287		Sep 12 04:45 PM
JOHANNA MERCIER	Officer	Sep 12 '24	Proposed Sale	83.78	29,357	2,459,577		Sep 12 04:43 PM
Mercier Johanna	Chief Commercial Officer	Aug 28 '24	Sale	78.03	9,513	742,299	105,466	Aug 29 03:23 PM
JOHANNA MERCIER	Officer	Aug 28 '24	Proposed Sale	78.03	9,513	742,299		Aug 28 04:18 PM
Mercier Johanna	Chief Commercial Officer	Aug 13 '24	Sale	73.98	5,490	406,150	114,979	Aug 14 02:23 PM
JOHANNA MERCIER	Officer	Aug 13 '24	Proposed Sale	73.98	5,490	406,150		Aug 13 04:27 PM
Parsey Merdad	Chief Medical Officer	Jul 01 '24	Sale	68.63	2,000	137,260	96,380	Jul 01 08:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GILD

Gilead Sciences, Inc

Upgrade your FINVIZ experience